Skip to main content
  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • First Disclosures
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Cancer Therapeutics
Molecular Cancer Therapeutics
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • First Disclosures
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Table of Contents

Spotlight on Clinical Response: Introduction

  • Spotlight on Clinical Response: Introduction
    Studies in target-based treatment
    Razelle Kurzrock
    Mol Cancer Ther September 1 2007 6 (9) 2385-2385; DOI:10.1158/1535-7163.MCT-06-9S

Spotlight on Clinical Response

  • Spotlight on Clinical Response
    Cutaneous castleman's disease responds to anti–interleukin-6 treatment
    Bilal Ahmed, Jaime A. Tschen, Philip R. Cohen, Mohamed H. Zaki, Peter L. Rady, Stephen K. Tyring, Robert E. Corringham and Razelle Kurzrock
    Mol Cancer Ther September 1 2007 6 (9) 2386-2390; DOI:10.1158/1535-7163.MCT-07-0256

Research Articles: Therapeutics, Targets, and Development

  • Research Articles: Therapeutics, Targets, and Development
    Characterization of novel inhibitors of histone acetyltransferases
    Elena D. Eliseeva, Vassil Valkov, Manfred Jung and Mira O. Jung
    Mol Cancer Ther September 1 2007 6 (9) 2391-2398; DOI:10.1158/1535-7163.MCT-07-0159

  • Research Articles: Therapeutics, Targets, and Development
    Improved low molecular weight Myc-Max inhibitors
    Huabo Wang, Dalia I. Hammoudeh, Ariele Viacava Follis, Brian E. Reese, John S. Lazo, Steven J. Metallo and Edward V. Prochownik
    Mol Cancer Ther September 1 2007 6 (9) 2399-2408; DOI:10.1158/1535-7163.MCT-07-0005

  • Research Articles: Therapeutics, Targets, and Development
    The novel melphalan prodrug J1 inhibits neuroblastoma growth in vitro and in vivo
    Malin Wickström, John Inge Johnsen, Frida Ponthan, Lova Segerström, Baldur Sveinbjörnsson, Magnus Lindskog, Henrik Lövborg, Kristina Viktorsson, Rolf Lewensohn, Per Kogner, Rolf Larsson and Joachim Gullbo
    Mol Cancer Ther September 1 2007 6 (9) 2409-2417; DOI:10.1158/1535-7163.MCT-07-0156

  • Research Articles: Therapeutics, Targets, and Development
    Structural modulation of reactivity/activity in design of improved benzothiophene selective estrogen receptor modulators: induction of chemopreventive mechanisms
    Bolan Yu, Birgit M. Dietz, Tareisha Dunlap, Irida Kastrati, Daniel D. Lantvit, Cassia R. Overk, Ping Yao, Zhihui Qin, Judy L. Bolton and Gregory R.J. Thatcher
    Mol Cancer Ther September 1 2007 6 (9) 2418-2428; DOI:10.1158/1535-7163.MCT-07-0268

  • Research Articles: Therapeutics, Targets, and Development
    Gambogic acid inhibits the catalytic activity of human topoisomerase IIα by binding to its ATPase domain
    Yuxin Qin, Linghua Meng, Chaoxin Hu, Wenhu Duan, Zhili Zuo, Liping Lin, Xiongwen Zhang and Jian Ding
    Mol Cancer Ther September 1 2007 6 (9) 2429-2440; DOI:10.1158/1535-7163.MCT-07-0147

  • Research Articles: Therapeutics, Targets, and Development
    Synthesis and biological activity of stable branched neurotensin peptides for tumor targeting
    Chiara Falciani, Monica Fabbrini, Alessandro Pini, Luisa Lozzi, Barbara Lelli, Silvia Pileri, Jlenia Brunetti, Stefano Bindi, Silvia Scali and Luisa Bracci
    Mol Cancer Ther September 1 2007 6 (9) 2441-2448; DOI:10.1158/1535-7163.MCT-07-0164

  • Research Articles: Therapeutics, Targets, and Development
    The combination of novel low molecular weight inhibitors of RAF (LBT613) and target of rapamycin (RAD001) decreases glioma proliferation and invasion
    Anita B. Hjelmeland, Kathryn P. Lattimore, Brian E. Fee, Qing Shi, Sarah Wickman, Stephen T. Keir, Mark D. Hjelmeland, David Batt, Darell D. Bigner, Henry S. Friedman and Jeremy N. Rich
    Mol Cancer Ther September 1 2007 6 (9) 2449-2457; DOI:10.1158/1535-7163.MCT-07-0155

  • Research Articles: Therapeutics, Targets, and Development
    The farnesyltransferase inhibitor R115777 (tipifarnib) in combination with tamoxifen acts synergistically to inhibit MCF-7 breast cancer cell proliferation and cell cycle progression in vitro and in vivo
    Lesley-Ann Martin, Julia E. Head, Sunil Pancholi, Janine Salter, Emma Quinn, Simone Detre, Stan Kaye, Angela Howes, Mitch Dowsett and Stephen R.D. Johnston
    Mol Cancer Ther September 1 2007 6 (9) 2458-2467; DOI:10.1158/1535-7163.MCT-06-0452

  • Research Articles: Therapeutics, Targets, and Development
    AZD6244 and doxorubicin induce growth suppression and apoptosis in mouse models of hepatocellular carcinoma
    Hung Huynh, Pierce K.H. Chow and Khee-Chee Soo
    Mol Cancer Ther September 1 2007 6 (9) 2468-2476; DOI:10.1158/1535-7163.MCT-07-0162

  • Research Articles: Therapeutics, Targets, and Development
    The radiosensitization effect of parthenolide in prostate cancer cells is mediated by nuclear factor-κB inhibition and enhanced by the presence of PTEN
    Yulan Sun, Daret K. St. Clair, Fang Fang, Graham W. Warren, Vivek M. Rangnekar, Peter A. Crooks and William H. St. Clair
    Mol Cancer Ther September 1 2007 6 (9) 2477-2486; DOI:10.1158/1535-7163.MCT-07-0186

  • Research Articles: Therapeutics, Targets, and Development
    Thiothymidine plus low-dose UVA kills hyperproliferative human skin cells independently of their human papilloma virus status
    Olivier Reelfs, Yao-Zhong Xu, Andrew Massey, Peter Karran and Alan Storey
    Mol Cancer Ther September 1 2007 6 (9) 2487-2495; DOI:10.1158/1535-7163.MCT-07-0166

  • Research Articles: Therapeutics, Targets, and Development
    Hypoxia modulation and radiosensitization by the novel dual EGFR and VEGFR inhibitor AEE788 in spontaneous and related allograft tumor models
    Christoph Oehler-Jänne, Wolfram Jochum, Oliver Riesterer, Angela Broggini-Tenzer, Giorgio Caravatti, Van Vuong and Martin Pruschy
    Mol Cancer Ther September 1 2007 6 (9) 2496-2504; DOI:10.1158/1535-7163.MCT-07-0253

  • Research Articles: Therapeutics, Targets, and Development
    The phosphatidylinositol 3-kinase inhibitor, PX-866, is a potent inhibitor of cancer cell motility and growth in three-dimensional cultures
    Amy L. Howes, Gary G. Chiang, Elizabeth S. Lang, Caroline B. Ho, Garth Powis, Kristiina Vuori and Robert T. Abraham
    Mol Cancer Ther September 1 2007 6 (9) 2505-2514; DOI:10.1158/1535-7163.MCT-06-0698

  • Research Articles: Therapeutics, Targets, and Development
    Effect of the histone deacetylase inhibitor LBH589 against epidermal growth factor receptor–dependent human lung cancer cells
    Arthur Edwards, Jiannong Li, Peter Atadja, Kapil Bhalla and Eric B. Haura
    Mol Cancer Ther September 1 2007 6 (9) 2515-2524; DOI:10.1158/1535-7163.MCT-06-0761

  • Research Articles: Therapeutics, Targets, and Development
    Histone deacetylase inhibitors selectively suppress expression of HDAC7
    Milos Dokmanovic, Gisela Perez, Weisheng Xu, Lang Ngo, Cathy Clarke, Raphael B. Parmigiani and Paul A. Marks
    Mol Cancer Ther September 1 2007 6 (9) 2525-2534; DOI:10.1158/1535-7163.MCT-07-0251

  • Research Articles: Therapeutics, Targets, and Development
    Reactive oxygen species mediated apoptosis of esophageal cancer cells induced by marine triprenyl toluquinones and toluhydroquinones
    Catherine E. Whibley, Kerry L. McPhail, Robert A. Keyzers, Michelle F. Maritz, Virna D. Leaner, Michael J. Birrer, Michael T. Davies-Coleman and Denver T. Hendricks
    Mol Cancer Ther September 1 2007 6 (9) 2535-2543; DOI:10.1158/1535-7163.MCT-06-0760

  • Research Articles: Therapeutics, Targets, and Development
    Kaempferol induces apoptosis in glioblastoma cells through oxidative stress
    Vivek Sharma, Christy Joseph, Soumya Ghosh, Anindita Agarwal, Manoj Kumar Mishra and Ellora Sen
    Mol Cancer Ther September 1 2007 6 (9) 2544-2553; DOI:10.1158/1535-7163.MCT-06-0788

  • Research Articles: Therapeutics, Targets, and Development
    Apoptosis-inducing antitumor efficacy of hexokinase II inhibitor in hepatocellular carcinoma
    Won Kim, Jung-Hwan Yoon, Jae-Min Jeong, Gi-Jeong Cheon, Tae-Sup Lee, Jong-In Yang, Su-Cheol Park and Hyo-Suk Lee
    Mol Cancer Ther September 1 2007 6 (9) 2554-2562; DOI:10.1158/1535-7163.MCT-07-0115

  • Research Articles: Therapeutics, Targets, and Development
    Involvement of specific matrix metalloproteinases during tumor necrosis factor/IFNγ–based cancer therapy in mice
    Maarten Van Roy, Philippe Van Lint, Ineke Van Laere, Ben Wielockx, Carole Wilson, Carlos López-Otin, Stephen Shapiro and Claude Libert
    Mol Cancer Ther September 1 2007 6 (9) 2563-2571; DOI:10.1158/1535-7163.MCT-07-0016

  • Research Articles: Therapeutics, Targets, and Development
    Selenium inhibition of survivin expression by preventing Sp1 binding to its promoter
    Jae Yeon Chun, Yan Hu, Elaine Pinder, Jianguo Wu, Fengzhi Li and Allen C. Gao
    Mol Cancer Ther September 1 2007 6 (9) 2572-2580; DOI:10.1158/1535-7163.MCT-07-0172

  • Research Articles: Therapeutics, Targets, and Development
    Enterolactone induces apoptosis in human prostate carcinoma LNCaP cells via a mitochondrial-mediated, caspase-dependent pathway
    Li-Hua Chen, Jing Fang, Huaixing Li, Wendy Demark-Wahnefried and Xu Lin
    Mol Cancer Ther September 1 2007 6 (9) 2581-2590; DOI:10.1158/1535-7163.MCT-07-0220

  • Research Articles: Therapeutics, Targets, and Development
    Quercetin enhances TRAIL-mediated apoptosis in colon cancer cells by inducing the accumulation of death receptors in lipid rafts
    Faiy H. Psahoulia, Konstantinos G. Drosopoulos, Lenka Doubravska, Ladislav Andera and Alexander Pintzas
    Mol Cancer Ther September 1 2007 6 (9) 2591-2599; DOI:10.1158/1535-7163.MCT-07-0001

  • Research Articles: Therapeutics, Targets, and Development
    A platelet biomarker for assessing phosphoinositide 3-kinase inhibition during cancer chemotherapy
    Rita K. Bowers, Philip Marder, Lisa J. Green, Candice L. Horn, Andrew L. Faber and James E. Thomas
    Mol Cancer Ther September 1 2007 6 (9) 2600-2607; DOI:10.1158/1535-7163.MCT-06-0746

Back to top
PreviousNext
Molecular Cancer Therapeutics: 6 (9)
September 2007
Volume 6, Issue 9
  • Table of Contents
  • About the Cover

Sign up for alerts

Issue Highlights

  • Cutaneous castleman's disease responds to anti–interleukin-6 treatment

Jump to

  • Spotlight on Clinical Response: Introduction
  • Spotlight on Clinical Response
  • Research Articles: Therapeutics, Targets, and Development
Advertisement
  • Most Cited
  • Most Read
Loading
  • Anti-KIT DNA Aptamer Labeling in GIST
  • SLFN11 Expression in Prostate Cancer
  • Single-cell RNA-seq to Uncover Metastatic Targets in PDAC
  • Tipifarnib as a Precision Therapy for HRAS-Mutant HNSCC
  • ARX788 Efficacy in HER2-low and T-DM1–resistant Cancers
More...
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About MCT

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Molecular Cancer Therapeutics
eISSN: 1538-8514
ISSN: 1535-7163

Advertisement